留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肺移植术后原发性移植物功能障碍的危险因素研究进展

胡春兰 于慧智 王净 李小杉 胡春晓

胡春兰, 于慧智, 王净, 等. 肺移植术后原发性移植物功能障碍的危险因素研究进展[J]. 器官移植, 2021, 12(3): 357-362. doi: 10.3969/j.issn.1674-7445.2021.03.016
引用本文: 胡春兰, 于慧智, 王净, 等. 肺移植术后原发性移植物功能障碍的危险因素研究进展[J]. 器官移植, 2021, 12(3): 357-362. doi: 10.3969/j.issn.1674-7445.2021.03.016
Hu Chunlan, Yu Huizhi, Wang Jing, et al. Research progress on risk factors of primary graft dysfunction after lung transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 357-362. doi: 10.3969/j.issn.1674-7445.2021.03.016
Citation: Hu Chunlan, Yu Huizhi, Wang Jing, et al. Research progress on risk factors of primary graft dysfunction after lung transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(3): 357-362. doi: 10.3969/j.issn.1674-7445.2021.03.016

肺移植术后原发性移植物功能障碍的危险因素研究进展

doi: 10.3969/j.issn.1674-7445.2021.03.016
基金项目: 

国家自然科学基金 8207011015

无锡市卫生健康委青年项目 Q202003

详细信息
    作者简介:

    胡春兰,女,1995年生,硕士研究生,住院医师,研究方向为肺缺血-再灌注损伤和移植物功能研究,Email: huchunlan00716@163.com

    通讯作者:

    胡春晓,男,1971年生,主任医师,研究方向为肺缺血-再灌注损伤、重要器官功能保护和ECMO辅助下肺移植围手术期的应用管理及脑损伤的机制,Email: huchunxiao91211@163.com

  • 中图分类号: R617, R563

Research progress on risk factors of primary graft dysfunction after lung transplantation

More Information
  • 摘要: 肺移植是治疗终末期肺疾病的唯一有效方式,但肺移植受者的早期预后远不如其他实体器官移植受者,其中原发性移植物功能障碍(PGD)是影响其预后的主要原因之一。PGD是肺移植术后早期发生的一种急性肺损伤,是导致肺移植受者术后早期死亡的主要原因。肺移植受者术后PGD发生的危险因素包括供者、受者、手术等多方面。本文对肺移植术后发生PGD的危险因素进行综述,旨在为临床提供参考。

     

  • [1] KHUSH KK, CHERIKH WS, CHAMBERS DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult heart transplantation report - 2019; focus theme: donor and recipient size match[J]. J Heart Lung Transplant, 2019, 38(10): 1056-1066. DOI: 10.1016/j.healun.2019.08.004.
    [2] CHRISTIE JD, VAN RAEMDONCK D, DE PERROT M, et al. Report of the ISHLT working group on primary lung graft dysfunction part I: introduction and methods[J]. J Heart Lung Transplant, 2005, 24(10): 1451-1453. DOI: 10.1016/j.healun.2005.03.004.
    [3] PORTEOUS MK, LEE JC. Primary graft dysfunction after lung transplantation[J]. Clin Chest Med, 2017, 38(4): 641-654. DOI: 10.1016/j.ccm.2017.07.005.
    [4] DIAMOND JM, ARCASOY S, KENNEDY CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on primary lung graft dysfunction, part Ⅱ: epidemiology, risk factors, and outcomes-a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation[J]. J Heart Lung Transplant, 2017, 36(10): 1104-1113. DOI: 10.1016/j.healun.2017.07.020.
    [5] JIN Z, SUEN KC, WANG Z, et al. Review 2: primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets[J]. J Anesth, 2020, 34(5): 729-740. DOI: 10.1007/s00540-020-02823-6.
    [6] BHARAT A, KREISEL D. Immunopathogenesis of primary graft dysfunction after lung transplantation[J]. Ann Thorac Surg, 2018, 105(3): 671-674. DOI: 10.1016/j.athoracsur.2017.11.007.
    [7] LIU Y, LIU Y, SU L, et al. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and Meta-analysis[J]. PLoS One, 2014, 9(3): e92773. DOI: 10.1371/journal.pone.0092773.
    [8] KUNTZ CL, HADJILIADIS D, AHYA VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study[J]. Clin Transplant, 2009, 23(6): 819-830. DOI: 10.1111/j.1399-0012.2008.00951.x.
    [9] PORTEOUS MK, LEE JC, LEDERER DJ, et al. Clinical risk factors and prognostic model for primary graft dysfunction after lung transplantation in patients with pulmonary hypertension[J]. Ann Am Thorac Soc, 2017, 14(10): 1514-1522. DOI: 10.1513/AnnalsATS.201610-810OC.
    [10] LOWERY EM, KUHLMANN EA, MAHONEY EL, et al. Heavy alcohol use in lung donors increases the risk for primary graft dysfunction[J]. Alcohol Clin Exp Res, 2014, 38(11): 2853-2861. DOI: 10.1111/acer.12553.
    [11] PELAEZ A, MITCHELL PO, SHAH NS, et al. The role of donor chronic alcohol abuse in the development of primary graft dysfunction in lung transplant recipients[J]. Am J Med Sci, 2015, 349(2): 117-123. DOI: 10.1097/MAJ.0000000000000361.
    [12] CAMARGO MORENO M, LEWIS JB, KOVACS EJ, et al. Lung allograft donors with excessive alcohol use have increased levels of human antimicrobial peptide LL-37[J]. Alcohol, 2019, 80: 109-117. DOI: 10.1016/j.alcohol.2018.11.003.
    [13] WILKEY BJ, ABRAMS BA. Mitigation of primary graft dysfunction in lung transplantation: current understanding and hopes for the future[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 54-66. DOI: 10.1177/1089253219881980.
    [14] EBERLEIN M, REED RM, BOLUKBAS S, et al. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation[J]. J Heart Lung Transplant, 2015, 34(2): 233-240. DOI: 10.1016/j.healun.2014.09.030.
    [15] PALLESCHI A, ROSSO L, MUSSO V, et al. Lung transplantation from donation after controlled cardiocirculatory death. systematic review and Meta-analysis[J]. Transplant Rev (Orlando), 2020, 34(1): 100513. DOI: 10.1016/j.trre.2019.100513.
    [16] VILLAVICENCIO MA, AXTELL AL, SPENCER PJ, et al. Lung transplantation from donation after circulatory death: United States and single-center experience[J]. Ann Thorac Surg, 2018, 106(6): 1619-1627. DOI: 10.1016/j.athoracsur.2018.07.024.
    [17] COSTA J, SHAH L, ROBBINS H, et al. Use of lung allografts from donation after cardiac death donors: a single-center experience[J]. Ann Thorac Surg, 2018, 105(1): 271-278. DOI: 10.1016/j.athoracsur.2017.07.023.
    [18] THUONG M, RUIZ A, EVRARD P, et al. New classification of donation after circulatory death donors definitions and terminology[J]. Transpl Int, 2016, 29(7): 749-759. DOI: 10.1111/tri.12776.
    [19] BOFFINI M, RICCI D, BONATO R, et al. Incidence and severity of primary graft dysfunction after lung transplantation using rejected grafts reconditioned with ex vivo lung perfusion[J]. Eur J Cardiothorac Surg, 2014, 46(5): 789-793. DOI: 10.1093/ejcts/ezu239.
    [20] LIU F, LU Y, WEI D, et al. Effect of ex vivo lung perfusion on storage of isolated lungs[J]. Ann Palliat Med, 2020, 9(2): 359-367. DOI: 10.21037/apm.2020.03.08.
    [21] WONG A, ZAMEL R, YEUNG J, et al. Potential therapeutic targets for lung repair during human ex vivo lung perfusion[J]. Eur Respir J, 2020, 55(4): 1902222. DOI: 10.1183/13993003.02222-2019.
    [22] TANE S, NODA K, TOYODA Y, et al. Bronchial-arterial-circulation-sparing lung preservation: a new organ protection approach for lung transplantation[J]. Transplantation, 2020, 104(3): 490-499. DOI: 10.1097/TP.0000000000002984.
    [23] OTO T, GRIFFITHS AP, ROSENFELDT F, et al. Early outcomes comparing Perfadex, Euro-Collins, and Papworth solutions in lung transplantation[J]. Ann Thorac Surg, 2006, 82(5): 1842-1848. DOI: 10.1016/j.athoracsur.2006.05.088.
    [24] AL-NAAMANI N, PAN HM, ANDERSON MR, et al. Thoracic visceral adipose tissue area and pulmonary hypertension in lung transplant candidates. the lung transplant body composition study[J]. Ann Am Thorac Soc, 2020, 17(11): 1393-1400. DOI: 10.1513/AnnalsATS.202003-247OC.
    [25] ANDERSON MR, UDUPA JK, EDWIN E, et al. Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study[J]. J Heart Lung Transplant, 2019, 38(12): 1246-1256. DOI: 10.1016/j.healun.2019.08.013.
    [26] LEE JC, CHRISTIE JD. Primary graft dysfunction[J]. Clin Chest Med, 2011, 32(2): 279-293. DOI: 10.1016/j.ccm.2011.02.007.
    [27] HU CX, CHEN WH, HE JX, et al. Lung transplantation in China between 2015 and 2018[J]. Chin Med J (Engl), 2019, 132(23): 2783-2789. DOI: 10.1097/CM9. 0000000000000543.
    [28] GEUBE MA, PEREZ-PROTTO SE, MCGRATH TL, et al. Increased intraoperative fluid administration is associated with severe primary graft dysfunction after lung transplantation[J]. Anesth Analg, 2016, 122(4): 1081-1088. DOI: 10.1213/ANE.0000000000001163.
    [29] WANG X, O'BRIEN ME, YU J, et al. Prolonged cold ischemia induces necroptotic cell death in ischemia-reperfusion injury and contributes to primary graft dysfunction after lung transplantation[J]. Am J Respir Cell Mol Biol, 2019, 61(2): 244-256. DOI: 10.1165/rcmb.2018-0207OC.
    [30] KIZILTUG H, FALTER F. Circulatory support during lung transplantation[J]. Curr Opin Anaesthesiol, 2020, 33(1): 37-42. DOI: 10.1097/ACO.0000000000000806.
    [31] MAGOULIOTIS DE, TASIOPOULOU VS, SVOKOS AA, et al. Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a Meta-analysis[J]. Gen Thorac Cardiovasc Surg, 2018, 66(1): 38-47. DOI: 10.1007/s11748-017-0836-3.
    [32] HAYANGA JWA, CHAN EG, MUSGROVE K, et al. Extracorporeal membrane oxygenation in the perioperative care of the lung transplant patient[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 45-53. DOI: 10.1177/1089253219896123.
    [33] HOETZENECKER K, BENAZZO A, STORK T, et al. Bilateral lung transplantation on intraoperative extracorporeal membrane oxygenator: an observational study[J]. J Thorac Cardiovasc Surg, 2020, 160(1): 320-327. DOI: 10.1016/j.jtcvs.2019.10.155.
    [34] FRICK AE, ORLITOVÁ M, VANSTAPEL A, et al. A novel experimental porcine model to assess the impact of differential pulmonary blood flow on ischemia-reperfusion injury after unilateral lung transplantation[J]. Intensive Care Med Exp, 2021, 9(1): 4. DOI: 10.1186/s40635-021-00371-1.
    [35] SUNDER T. Extracorporeal membrane oxygenation and lung transplantation[J]. Indian J Thorac Cardiovasc Surg, 2021, 19: 1-11. DOI: 10.1007/s12055-020-01099-5.
    [36] MITZMAN B. Commentary: taking matters into your own hands: venoarterial extracorporeal membrane oxygenation for controlled reperfusion during lung transplantation[J]. J Thorac Cardiovasc Surg, 2020, 160(1): 330-331. DOI: 10.1016/j.jtcvs.2019.11.037.
    [37] PENA JJ, BOTTIGER BA, MILTIADES AN. Perioperative management of bleeding and transfusion for lung transplantation[J]. Semin Cardiothorac Vasc Anesth, 2020, 24(1): 74-83. DOI: 10.1177/1089253219869030.
    [38] SEAY T, GUINN N, MAISONAVE Y, et al. The association of increased FFP: RBC transfusion ratio to primary graft dysfunction in bleeding lung transplantation patients[J]. J Cardiothorac Vasc Anesth, 2020, 34(11): 3024-3032. DOI: 10.1053/j.jvca.2020.05.043.
    [39] SYRETT AJ, HUANG A. Transfusion and primary graft dysfunction after lung transplantation: all about the ratio?[J]. J Cardiothorac Vasc Anesth, 2020, 34(11): 3033-3035. DOI: 10.1053/j.jvca.2020.07.012.
    [40] 胡春晓, 王志萍, 许波, 等. 肺移植术中肺动脉高压的麻醉管理[J]. 中华器官移植杂志, 2019, 40(3): 189-192. DOI: 10.3760/cma.j.issn.0254-1785.2019.03.017.

    HU CX, WANG ZP, XU B, et al. Anesthesia management of pulmonary hypertension during lung transplantation[J]. Chin J Organ Transplant, 2019, 40(3): 189-192. DOI: 10.3760/cma.j.issn.0254-1785.2019.03.017.
    [41] KACHULIS B, MITREV L, JORDAN D. Intraoperative anesthetic management of lung transplantation patients[J]. Best Pract Res Clin Anaesthesiol, 2017, 31(2): 261-272. DOI: 10.1016/j.bpa.2017.04.004.
    [42] 中华医学会麻醉学分会"肺移植术麻醉管理专家共识"工作小组. 肺移植术麻醉管理专家共识[J]. 中华麻醉学杂志, 2020, 40(7): 771-778. DOI: 10.3760/cma.j.cn131073.20200508.00702.

    Task Force on Anaesthesia Management for Lung Transplantation of Branch of Anesthesiology of Chinese Medical Association. Expert consensus on anaesthesia management for lung transplantation[J]. Chin J Anesthesiol, 2020, 40(7): 771-778. DOI: 10.3760/cma.j.cn131073.20200508.00702.
    [43] YAMADA Y, LAUBE I, JANG JH, et al. Sevoflurane preconditioning protects from posttransplant injury in mouse lung transplantation[J]. J Surg Res, 2017, 214: 270-277. DOI: 10.1016/j.jss.2017.03.021.
    [44] MARTIN AK, YALAMURI SM, WILKEY BJ, et al. The impact of anesthetic management on perioperative outcomes in lung transplantation[J]. J Cardiothorac Vasc Anesth, 2020, 34(6): 1669-1680. DOI: 10.1053/j.jvca.2019.08.037.
  • 加载中
图(1)
计量
  • 文章访问数:  157
  • HTML全文浏览量:  73
  • PDF下载量:  26
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-02-13
  • 网络出版日期:  2021-05-19
  • 刊出日期:  2021-05-15

目录

    /

    返回文章
    返回